Breakthrough RCT Published in Leading ADA Journal “Diabetes Care” Shows Multi-Modality Topical Wound Oxygen (TWO2) Therapy is Six-Times More Effective Healing & Reducing Recurrence of Diabetic Foot Ulcers
AOTI Inc. today announced that a state-of-the-art Randomized Controlled Trial (RCT) demonstrating the efficacy of its unique multi-modality cyclical pressure Topical Wound Oxygen (TWO2) therapy in healing and reducing recurrence of Diabetic Foot Ulcers (DFU) has been...
AOTI Inc. Awarded New Five-Year Federal Supply Schedule Contract by the Department of Veterans Affairs
OCEANSIDE, Calif., June 19, 2019 /PRNewswire/ — AOTI Inc. today announced that it has been awarded a new five-year Federal Supply Schedule (FSS) contract for its patented Topical Wound Oxygen (TWO2) therapy by the National Acquisition...
AOTI’s Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading Worldwide Wound Care Conferences
It is clear there is a growing tsunami of interest in our products and their unprecedented complete healing benefits. We expect and hope that as our latest state-of-the-art Randomized Controlled Trial (RCT) is published that TWO2therapy will be made available to all chronic wound patients worldwide.
AOTI Enters Into Multi-Million USD Strategic Relationship for Chinese Market
OCEANSIDE, Calif., Jan. 18, 2019 /PRNewswire/ — AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen...